| Title： | Expert consensus on the use of polydeoxyribonucleotide in dermatology（2024） |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Users are clinicians, dietitians, caregivers, health managers and other professionals. |
| Evidence classification method： | GRADE Evidence Grading |
| Development unit： | Department of Dermatology, Southwest Hospital, Army Medical University (Third Military Medical University) |
| Registration time: | 2024-01-23 |
| Registration number： | PREPARE-2024CN204 |
| Purpose of the guideline: | Polydeoxyribonucleotide (PDRN) is a DNA derivative composed of a mixture of polynucleotides. PDRN exerts anti-inflammatory, anti-apoptotic, anti-melanogenic, collagen regeneration and angiogenic effects through activation of the adenosine A2A receptor or the “salvage pathway.” In recent years, PDRN has been extensively utilized in dermatology, particularly in the field of cosmetic dermatology. To ensure uniformity in its application, the PDRN Clinical Application Consensus Expert Group has meticulously developed a consensus document based on extensive discussions and the latest research findings from both domestic and international sources. The document aims to provide practitioners with clear guidance and recommendations on the clinical application of PDRN, including its mechanism of action, effectiveness, safety, indications, and contraindications. |
Latest registration
